Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 6Leukemia, Myeloid, Acute 4Uveal Melanoma 2Lymphoma 2Leukemia 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Recurrence 1Rectal Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Meningeal Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Kidney Diseases 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 28Rituximab 23fludarabine 14fludarabine phosphate 12Specimen Handling 11obinutuzumab 10ibrutinib 10Magnetic Resonance Spectroscopy 10Prednisone 8Doxorubicin 8tocilizumab 7polatuzumab vedotin 7X-Rays 7Whole-Body Irradiation 7Phantoms, Imaging 7Mycophenolic Acid 7Etoposide 7Biopsy 7venetoclax 6glofitamab 6Melphalan 6Lenalidomide 6Bendamustine Hydrochloride 6pirtobrutinib 5acalabrutinib 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × Interleukin-2 × 90 days × Clear all
NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Artiva Biotherapeutics, Inc.

Phase 1/2 Completed
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡